Work

LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study

Year: 2023

Type: conference-abstract

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.10.075

Authors: K. Shitara, S.Y. Rha, L.S. Wyrwicz, T. Oshima, N. Karaseva, M. Osipov, H. Yasui, H. Yabusaki, S. Afanasyev, Y-K. Park, S-E. Al-Batran, T. Yoshikawa, P.E. Yanez Weber, M. Di Bartolomeo, S. Lonardi, X. Fang, C-S. Shih, P. Bhagia, Y-J. Bang

Institutions: National Cancer Center Hospital East, Yonsei University Health System, Yonsei Cancer Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Kanagawa Cancer Center, City Clinical Oncology Center, Kobe City Medical Center General Hospital, Niigata Cancer Center Hospital, Tomsk Cancer Research Institute, Chonnam National University Hwasun Hospital, Institute of Clinical Cancer Research, Krankenhaus Nordwest, National Cancer Center Hospital, Universidad de La Frontera, Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Oncologico Veneto, Merck & Co., Inc., Rahway, NJ, USA (United States), Seoul National University

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Merck, Taiho Pharmaceutical, Boehringer Ingelheim Japan, Daiichi-Sankyo, Eisai, Astellas Foundation for Research on Metabolic Disorders, Ono Pharmaceutical, Chugai Pharmaceutical, MSD K.K., Pfizer Pharmaceuticals, Janssen Pharmaceuticals, Daiichi Sankyo Europe

OpenAlex ID: W4387809557

Cites:

Cited by: 34

Related to: 10